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Abstract
Purpose To investigate the long-term
effectiveness and safety of botulinum
neurotoxin A (BoNT-A) treatment in patients
with blepharospasm (BEB), hemifacial spasm
(HFS), and entropion (EN) and to use for the
first time two modified indexes, ‘botulin toxin
escalation index-U’ (BEI-U) and ‘botulin toxin
escalation index percentage’ (BEI-%), in the
dose-escalation evaluation.
Methods All patients in this multicentre
study were followed for at least 10 years and
main outcomes were clinical efficacy, duration
of relief, BEI-U and BEI-%, and frequency of
adverse events.
Results BEB, HFS, and EN patients received
a mean BoNT-A dose with a significant inter-
group difference (Po0.0005, respectively). The
mean (±SD) effect duration was statistically
different (P¼ 0.009) among three patient
groups. Regarding the BoNT-A escalation
indexes, the mean (±SD) values of BEI-U and
BEI-% were statistically different (P¼ 0.035
and 0.047, respectively) among the three
groups. In BEB patients, the BEI-% was
significantly increased in younger compared
with older patients (P¼ 0.008). The most
frequent adverse events were upper lid ptosis,
diplopia, ecchymosis, and localized bruising.
Conclusions This long-term multicentre
study supports a high efficacy and good safety
profile of BoNT-A for treatment of BEB, HFS,
and EN. The BEI indexes indicate a
significantly greater BoNT-A-dose escalation
for BEB patients compared with HFS or EN
patients and a significantly greater BEI-% in
younger vs older BEB patients. These results
confirm a greater efficacy in the elderly and
provide a framework for long-term studies
with a more flexible and reliable evaluation of
drug-dose escalation.
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Introduction
Benign essential blepharospasm (BEB) is a focal
cranial dystonia characterized by excessive
involuntary contractions of the eyelid muscles.
It is usually bilateral, although it may be
unilateral briefly at onset.1–3 Initial symptoms
include unpleasant sensations, eyelid fluttering,
and increased blink rate in response to stimuli,
progressing eventually to chronic involuntary
spasms in both eyes.4 Quality of life may be
significantly impaired, with increased difficulty
in reading, writing, and driving.5 BEB is
estimated to affect between 16 and 133 out of
1 000 000 individuals in the general
population6,7 and is increasingly being
recognized as cause of visual disability
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responsible for about 32 out of 100 000 people.8,9 An
estimated 20 000–50 000 people are affected in the USA,
with approximately 2000 new cases of BEB diagnosed
annually.7 Typically beginning in the fifth or sixth decade
of life, it affects women more frequently than men (3 : 1)10
and the elderly.6
Botulinum neurotoxin A (BoNT-A) therapy for
strabismus was introduced by Scott11 in the early 1980s,
and in 1989 the Food and Drug Administration approved
BoNT-A for ophthalmologic and neurologic use in
treating strabismus, blepharospasm, and hemifacial
spasm (HFS).12 Since then, BoNT-A has replaced eyelid
surgery as the first-line therapy for BEB,13–17 and has
become the treatment of choice, as it is very successful in
controlling eyelid spasms.17–29 Although some authors
have reported decreasing effectiveness with prolonged
use,23,30 others have not observed this in the majority of
patients.24,31 There is no evidence that prolonged
treatment has any adverse effects related either to the
chemodenervation of adjacent non-target muscle groups
by the toxin or to the injection technique. Complications
include localized bruising, ecchymosis, ptosis, exposure
keratopathy, diplopia, mid-facial weakness,
lagophthalmos, and dry eye.
HFS, a form of segmental myoclonus, is typically
characterized by involuntary unilateral tonic and clonic
contractions of the face. Onset is usually in the fifth and
sixth decades and occurs more commonly in women
(2 : 1) with an overall prevalence of about 10 : 100 000.
However, in some populations, such as Asians, the
prevalence is much higher.32 Some patients may be
genetically predisposed to developing HFS,33 but most
cases are sporadic.9 Unlike blepharospasm, HFSs persist
during sleep and are not related to hypersensory input.
The anatomical basis for the spasms is believed to be
mechanical irritation of the facial nerve at its exit root
by compression from one or more adjacent arteries or
veins. The condition may be bilateral in rare instances,
and can cause significant cosmetic and functional
disability. Although neurosurgical treatment is available,
the potential complications and relatively high
recurrence rate have made botulinum toxin A the
preferred symptomatic treatment for HFS.34–39 As HFS
rarely remits spontaneously,40 most patients need to
continue BoNT-A treatment for many years, if not for the
rest of their lives. The long-term efficacy and safety of
BoNT-A are, therefore, increasingly important questions.
Few of the numerous published studies assessing
BoNT-A treatment for HFS34,36,37,40,41 included patients
with serial treatment spanning several years and none
had follow-up past 5 years.
Spastic entropion (EN) is a form of EN in which the
lower eyelid margin is turned in, with a riding up of the
pre-tarsal orbicularis muscle, and often accompanies
involutional EN. In older patients with pre-existing lid
laxity, ocular irritation after ocular surgery can
sometimes cause a reflexive orbicularis muscle spasm,
resulting in muscle override and EN that often resolves
after a few weeks or months. Temporary relief can be
achieved by weakening lower eyelid muscle tone with
5–10 U botulinum toxin injected into the pre-tarsal or
pre-septal orbicularis muscle.42–45 This can completely
eliminate the EN for up to 3–4 months. Botulinum toxin
is a highly effective temporary EN treatment with few
complications and no adverse effects on the results of
surgical EN repair.39
Treatment of blepharospasm and HFS with BoNT-A
has been found to alleviate symptoms and enhance
quality of life.5,46 Whereas most patients show long-term
clinical improvement with repeated injections, however,
some eventually stop responding and others fail to
respond at all.13,24,30 Although BoNT-A has been used for
many years to treat focal dystonia-like blepharospasm,
cervical dystonia, and HFS, there are little data on its
long-term efficacy.47 Furthermore, earlier studies have
explored the limitations of BoNT-A; in particular, the
development of secondary resistance to therapy.48 Two
recent reports suggest that higher doses and long-term
use with shorter duration between treatments increase
the risk of antibody formation and treatment failure.49,50
Recently, two studies also confirmed that higher doses of
BoNT-A than recommended (50 U  eye) may be
needed for some patients.51,52 Therefore, it is important to
determine whether efficacy with high-dose therapy can
be sustained for long treatment periods without
developing resistance, and whether the risk of
complications is increased.
The aim of this multicentre study was to investigate
the long-term effectiveness and safety of BoNT-A
treatment in patients with BEB, primary HFS, and EN.
We followed up regularly with patients for at least 10
years to compare the duration of relief, the number of
doses needed, clinical efficacy, frequency of adverse
reactions, anxiety and depressive symptoms, and
antidepressant use among the three patient groups.
In particular, we examined the variations in therapeutic
dosage using new, modified indexes already used in
other drug therapies and considered effective in the
evaluation of drug-dose escalation.53 Finally, we assessed
the effectiveness of BoNT-A treatment in relationship to
patient variables, such as age and gender.
Materials and methods
This multicentre study was conducted at the
Ophthalmology Section, Department of Clinical
Neuroscience of Palermo University, Italy and at the
Service d’Ophtalmologie, Hoˆpital Foch, Suresnes, Paris,
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France. Institutional Review Board approval was
obtained for this prospective study. All patients received
a diagnosis of BEB, primary HFS, or EN according to
published criteria and began treatment with BoNT-A
(Botox, Allergan, Irvine, California, USA) injections
between 1 January 1995 and 31 December 1998. Patients
who were followed up for at least 10 years were enrolled
in this prospective study. Both centres used standard
methods for recording information, injecting BoNT-A,
and assessing treatment effectiveness.54 The injections
were performed by two experienced surgeons (NG and
SD) one for each centre; site of injection and the BoNT-A
dosage were determined according to Helveston.55
Patients with other neurological defects, including
ocular motility or eyelid problems or facial spasm
grade o2, were excluded from the study.
A total of 173 patients completed the 10-year follow-
up: 83 patients with BEB, 65 with HFS, and 25 with EN.
Of these, 18 did not attend follow-up visits for 12 months
or more and were thus considered as ‘dropouts.’ Of the
18 dropouts, 6 had not discontinued BoNT-A therapy, but
had switched to other treatment centres closer to their
homes. Reasons for treatment discontinuation included
death from other causes (five patients) and unsatisfactory
results (four patients). Three patients dropped out for
unknown reasons.
To assess the long-term effectiveness and safety of
BoNT-A, we reviewed patients’ medical records for the
10 years of follow-up and collected the following
demographic and clinical patient data for each group:
age and gender, concomitant systemic diseases, duration
of disease, earlier facial paralysis, date of BoNT-A
injections, total dose for each injection, number and
location of injection sites, duration of effect (defined as
the interval between treatment and the recurrence of
symptoms severe enough to prompt patients to receive
another injection), quality of the effect induced by the
preceding treatment, and occurrence and duration of
adverse effects. Before each injection session, patients
were questioned about the results of the earlier session.
The severity of diagnosis and the subjective efficacy of
the BoNT-A treatment were measured using a patient
self-evaluation scale. At each injection visit, changes in
the patient’s status were scored as no change (muscle
spasms that interfered with activities of daily living or
social tasks in such a way that patients continued to be
socially embarrassed), moderate improvement
(reduction in the frequency and duration of spasms, so
that they interfered only slightly with activities of daily
living or social tasks), or marked improvement (spasms
in the injected muscle had ceased altogether, so that they
no longer interfered with activities of daily living or
social tasks). Furthermore, the self-administered
questionnaire included three questions about the
frequency of anxiety or depressive symptoms and use of
antidepressants in the three groups of patients.
For age analysis, patients were categorized into two
groups: under 65 years old and X65 years old. To assess
the inter- and intra-group variations among BEB, HFS,
and EN patients for scheduling dosage regimens of
BoNT-A, we used two new, modified indexes already
used in other fields of drug therapy and considered
effective in evaluation of drug-dose escalation.53 For the
calculation of these indexes (evaluated in U and in per
cent of BoNT-A-dose escalation), the botulinum toxin
starting dose (BSD), the botulinum toxin maximum dose
(BMD), and the total days of duration effect between
treatments were recorded for each patient. The
botulinum toxin escalation index in U (BEI-U) was
calculated as the mean increase in botulinum toxin
dosage (in U) using the following formula: (BMD–BSD)/
days. The botulinum toxin escalation index percentage
(BEI-%) was calculated as the mean percentage of
increase in botulinum toxin dosage from BSD using the
following formula: [(BMD–BSD)/BSD]/(days 100).52
Any local and systemic side effects attributable to
BoNT-A therapy were evaluated at each injection time.
Statistical analysis
Statistical analysis was performed using Epi Info
software, version 3.2.2 (Centers for Disease Control and
Prevention, Atlanta, GA, USA) and SPSS Software
(version 14.0, SPSS Inc., Chicago, IL, USA). The results
are expressed as mean±standard deviation. To compare
parametric variables among patient groups, univariate
analysis of variance test was used and post hoc analysis
with the Bonferroni test was used to determine whether
there were multiple differences. When a normal
distribution was not expected, the Kruskal–Wallis test
was used. Changes between baseline and follow-up
values were compared using the paired Wilcoxon signed-
rank test. Categorical variables were compared using the
w2 test and Fisher’s exact test, as needed. A two-tailed
P-value o0.05 was considered as statistically significant.
Results
Of the 155 patients treated with BoNT-A who completed
the 10-year course of follow-up, 73 (22M/51F) patients
had BEB, 58 (21M/37F) had HFS, and 24 (12M/12F) had
EN (Table 1). There were more females (Po0.05)
compared with males in both the BEB and HFS groups,
but not in the EN group. There was a significant
difference in mean age among the three groups, with
patients in the EN group older (P¼ 0.024) compared with
the BEB and HFS patient groups (Table 1). Furthermore,
duration of the disease was significantly shorter in the
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EN patient group (P¼ 0.001). No difference was found
among patient groups for concomitant systemic disease,
though earlier facial paralysis was more frequently found
in the HFS patient group (P¼ 0.004) (Table 1).
BEB, HFS, and EN patient groups received a total of
529, 391, and 64 treatments and a mean treatment
number of 8.7 (±7.1), 7.8 (±5.5), and 2.7 (±3.2),
respectively, with a significant difference among
diagnosis groups (P¼ 0.006). Post hoc analysis
(Bonferroni test) showed significant differences between
the EN group and both BEB and HFS groups (P¼ 0.005
and 0.020, respectively) (Table 2). The frequency of
patients who needed only one dose of BoNT-A were
14/73 (19.2%) for BEB, 9/58 (15.5%) for HFS, and
13/24 (54.2%) for EN, with a statistical significant
difference in favour of the EN patient group (Po0.0005).
On average, each patient received a mean BoNT-A dose
of 28.2 (±12.2) U for BEB, 18.7 (±9.4) U for HFS, and 10.6
(±4.7) U for EN patients, with a statistically significance
difference among the groups (Po0.0005). Post hoc
analysis (Bonferroni test) showed significant differences
between the BEB group and both HFS and EN groups
(Po0.0005 in both cases) and between the HFS group
and EN group (P¼ 0.005) (Table 2). The mean (±SD)
effect duration was 18.2 (±12.3) weeks for BEB, 20.6
(±11.6) weeks for HFS, and 13.7 (±7.0) weeks for EN,
with statistically significant inter-group difference
(P¼ 0.009) (Table 2).
For analysis of the BoNT-A escalation index, the mean
(±SD) values of BEI-U were 0.027 (±0.05), 0.008 (±0.01),
and 0.005 (±0.01) for the BEB, HFS, and EN, respectively,
groups with a statistically significant difference among
the groups (P¼ 0.035). Post hoc analysis (Bonferroni test)
showed significant differences between the BEB group
and both HFS and EN groups (P¼ 0.028 and 0.022,
respectively). The mean (±SD) values of BEI-% were
0.169 (±0.24), 0.053 (±0.08), and 0.068 (±0.10) for BEB,
HFS, and EN groups, respectively, with a statistical
significant difference among groups (P¼ 0.047) (Table 2).
Significant intra-group differences were found for
mean dosages, which increased significantly (Po0.05)
after the first three or four doses of treatment for both
BEB and HFS patient groups. No significant difference
was found in the duration effect between BEB and HFS
patient groups (Figures 1 and 2).
In 23/73 (31.5%), 18/58 (31.0%), and 1/24 (4.2%)
patients with BEB, HFS, and EN, respectively, local
adverse events occurred (Table 3). The most frequently
reported adverse reaction was upper lid ptosis, followed
by diplopia, ecchymosis, and localized bruising on the
side of injection. Although there was a significant
difference (P¼ 0.023) in total side effects among three
Table 2 Na treatments, duration of effect, dosages and dose escalation indexes of BoNT-A in patients with BEB, HFS, and EN
BEB 73 HFS 58 EN 24 Pa
Na treatments (mean±SD) 8.7 (7.1) 7.8 (5.5) 2.7 (3.2) 0.006
Overall duration effect (weeks, mean±SD) 168 (118) 164 (102) 71 (50) 0.003
Duration effect for patient (weeks, mean±SD) 18.2 (12.3) 20.6 (11.6) 13.7 (7.0) 0.009
BoNT-A dose for patient (U, mean±SD) 28.2 (12.2) 18.7 (9.4) 10.6 (4.7) o0.0005
BEI-U (mean±SD) 0.027 (0.05) 0.008 (0.01) 0.005 (0.01) 0.035
BEI-% (mean±SD) 0.169 (0.24) 0.053 (0.08) 0.068 (0.10) 0.047
aAnalysis of variance test.
Table 1 Demographic and clinical characteristics of patients with BEB, HFS. and EN in treatment with BoNT-A
BEB 73 HFS 58 EN 24 P
Gender (M/F) 22/51 21/37 12/12 o0.05a,b
0.209a
Age (mean±SD, years) 71.4 (12.3) 71.7 (11.4) 78.6 (8.9) 0.024c
Patients with age o65 years 18/73 13/58 2/24 0.230a
Previous facial paralysis 1/73 8/58 0/24 0.004a
Duration of disease (mean±SD, years) 11.2 (6.7) 13.3 (8.8) 6.5 (4.8) 0.001c
Concomitant systemic disease 24/73 27/58 11/24 0.232a
Neurological 1 6 1
Cardiovascular and metabolic 16 16 4 0.090a
Others 7 5 6
aw2 test and Fisher’s exact test, as needed.
bIntra-group analysis.
cAnalysis of variance test.
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patient groups because of the low incidence of
complications in the EN group, the incidence of side
effects was similar in the BEB and HFS groups. Of the 42
patients with adverse effects, 32 had only one adverse
event and two patients had more than two complications.
Local adverse events were rated as mild to moderate and
resolved without sequelae, but they interfered with daily
activities and social tasks in approximately 30% of cases.
The mean dose of BoNT-A was not significantly higher
for injection sessions that induced adverse reactions than
for sessions that did not (P¼ 0.480).
Symptoms of anxiety were more frequently found in
the HFS patient group (P¼ 0.045), but there were no
significant differences in depressive mood or use of
antidepressants among patient groups.
According to patients’ subjective impressions, nearly
all treatments improved BEB and HFS, with response
rates of 96 and 98%, respectively. BoNT-A was also highly
effective in temporary treatment of spastic EN. No
systemic side effects of BoNT-A treatment were noted, a
finding consistent with the medical reports (no cases of
anaphylaxis or death). There were no significant gender-
based differences between the three patient groups. In
patients with blepharospasm, the BEI-% was significantly
increased in younger compared with older patients
(P¼ 0.008), whereas no age group differences were found
in HFS patients. The intra-group analysis performed by
age group and diagnosis showed that the mean dosages
of BoNT-A were significantly increased during follow-up
in older BEB and HFS patients (Po0.05). Furthermore,
the duration effect increased significantly in these
patients as treatment progressed (Po0.05). No
differences in duration effect and dosage were found in
younger BEB and HFS patients. No difference in the
incidence of adverse effects was found according in the
age group analysis for BEB (P¼ 0.848) and HFS
(P¼ 0.166) patients.
Discussion
Our multicentre study provided a larger sample of
patients with BEB, HFS, and spastic EN receiving BoNT-
A treatment than would be possible with one centre
alone. It also had the advantage of a 10-year follow-up.
The study data support the high efficacy and good safety
profile of BoNT-A for treatment of BEB, HFS, and EN
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Figure 1 Variation of duration effect (mean number of weeks)
over time (interval T1–T15) in the BEB and HFS patient groups
Table 3 Local side effects of BoNT-A treatment in patients with BEB, HFS, and EN
BS ESF EN Pa
Patients with local side effects 23/73 (31.5) 18/58 (31.0) 1/24 (4.2) 0.023
Ecchymosis 6 (8.2) 1 (1.7) 0 0.105
Localized bruising 2 (2.7) 4 (6.9) 0 0.267
Ptosis 14 (19.2) 10 (17.2) 0 0.071
Dry eye 2 (2.7) 1 (1.7) 0 0.692
Diplopia 4 (5.4) 5 (8.6) 0 0.311
Mouth droop 0 1 (1.7) 0 0.431
Photophobia 1 (1.4) 2 (3.4) 0 0.523
Blurred vision 1 (1.4) 0 0 0.568
Lacrimation 0 0 1 (4.2) 0.064
aw2 test and Fisher’s exact test, as needed.
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without increased risk of side effects. A total of 96% of
patients with BEB, 98% of patients with HFS, and 100%
of patients with EN had significant relief of their
symptoms.
Although BoNT-A has been used to treat BEB, HFS,
and EN for several years, most available studies describe
relatively short treatment courses and follow-up, with
few patients receiving continuous treatment throughout
the study.16,25,29,36,45,56 Little work has been done to track
longer-term outcomes in terms of response rates,
duration of improvement, and long-term adverse
reactions.28,40,47,57,58 In our long-term, multicentre study,
we have obtained at least a 96% response rate and a
mean duration of improvement of 18, 21, and 14 weeks
for BEB, HFS, and EN, respectively. This outcome
compares well with shorter-term study results. The
effectiveness of BoNT-A treatment in relieving the
symptoms of BEB, HFS, and EN, as measured by the
response rate and average duration of improvement,
remained unchanged over the treatment years. Hence,
BoNT-A use produces substantial, sustained relief over
time for BEB and HFS. Our study also confirms results of
other studies showing that botulinum toxin is a highly
effective temporary treatment for EN, with few
complications and no adverse effects on the results of
surgical EN repair.39,45,59
The clinical reestablishment of muscle function after
BoNT-A injections requires repeated injections over long
periods.49,50 The onset of resistance to botulinum toxin
over time may be due to the immunological properties of
the toxin that lead to the stimulation of antibody
production, thus rendering further treatments
ineffective.48–51 Greene and Fahn49 found that patients
resistant to botulinum toxin received more booster
injections early after treatment, as well as higher doses
compared with responsive patients. These authors,
therefore, recommended that the lowest possible
effective dose should be used, with treatment intervals of
at least 3 months, and that booster injections be avoided.
Atassi and Oshima50 confirmed these findings by
showing an association of high-dose, high-frequency
botulinum toxin injections with increased antigenicity.
In our study, we have for the first time used two
indexes that are already widely used in other drug
therapy studies53,60 for assessing the medium,
long-term effects of a specific treatment with uncertain
duration. These indexes, namely ‘botulin toxin escalation
index-U’ (BEI-U) and ‘botulin toxin escalation index
percentage’ (BEI-%), include several factors, but are easy
to calculate for different settings and periods and can be
used to compare data in clinical trials. This dynamic tool
can be useful to describe a trend in botulinum toxin
treatment response, in which multiple factors can be
identified in the clinical records, and can be used
for the entire treatment period or for restricted
periods of time.
In our prospective study, we found an increase in
mean dosages for BEB and HFS patients with no
statistically significant change in duration of relief during
the follow-up period. Furthermore, subgroup analysis
according to age (o orX65 years) indicates a significant
increase in duration of relief and mean doses over the
follow-up period in older but not younger BEB and HFS
patients. Using BEI-U and BEI-%, we found a
significantly greater BoNT-A-dose escalation for BEB
patients compared with HFS or EN patients. In
particular, a significantly greater BEI-% was found in
younger vs older BEB patients.
These results suggest early underdosing, but only in
older BEB and HFS patients. Furthermore, as reported for
BoNT-A (Dysport) treatment by Truong et al,61 the BEI-U
and BEI-% data confirm a greater efficacy in the elderly,
who may have lower muscle bulk than younger people
and who may require a lower-dose escalation to achieve
optimal benefit.
Our data provide a framework for long-term studies in
which a more flexible and reliable evaluation of dose
escalation as a function of variable treatment time for
different diseases is required.
Consistent with earlier studies,9,39,62 30% of our
patients showed one or more side effects, including
eyelid ptosis, ecchymosis, diplopia, and localized
bruising occurred. Adverse events were rated as mild to
moderate and resolved without sequelae. There was no
evidence that prolonged treatment or age increased
adverse effects. We found that anxiety was more frequent
in the HFS patient group (P¼ 0.045), emphasizing the
need for treatments such as BoNT-A injections, which
have showed to improve the quality of life and reduce
the severity of depressive symptoms in patients with
blepharospasm.46
Some potential limitations of our study include the
retrospective nature of our analysis and the use of a
patient self-evaluation scale, which have earlier been
used effectively,58 rather than an observer-based rating to
determine the effect of BoNT-A treatment on BEB, HFS,
and EN patients. However, the large effect reported in
other studies (over 90% of patients benefit) makes it
difficult and probably unethical to perform controlled
trials for the efficacy of BoNT-A. Future trials should
explore technical factors, such as the optimal treatment
intervals and the effects of different injection techniques,
doses, botulinum toxin types, and formulations. Other
issues include service delivery, quality of life, long-term
efficacy, safety, and immunogenicity. Although
botulinum neurotoxin injections are currently the
mainstay of therapy, other therapies are on the
horizon.17,38,46,63,64
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